Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeOnc Technologies Holdings, Inc. - Common Stock (NQ:NTHI)

7.710 +0.700 (+9.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 176,297
Open 7.010
Bid (Size) 2.990 (200)
Ask (Size) 10.75 (500)
Prev. Close 7.010
Today's Range 7.010 - 7.900
52wk Range 3.200 - 25.00
Shares Outstanding 19,474,303
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
New to The Street Broadcasts Nationwide Tonight on Bloomberg Television Featuring NeOnc ($NTHI), Metaterra Holdings Inc., CISO Global ($CISO), and NRx Pharmaceuticals ($NRXP)
Via ACCESS Newswire
News headline image
NeOnc Technologies Reports Updated Clinical Results
Expanded Clinical Experience Demonstrates Additional Long-Term Survival and Radiographic Remission in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100 
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire

Performance

YTD
-36.3%
-36.3%
1 Month
+5.3%
+5.3%
3 Month
-35.4%
-35.4%
6 Month
+72.1%
+72.1%
1 Year
-36.3%
-36.3%

More News

Read More
News headline image
NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Reports Updated Clinical Results
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC
Via ACCESS Newswire
News headline image
NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
New to The Street to Broadcast Tonight on Fox Business 10:30 PM PST Featuring NeOnc Technologies, FLOKI, XION, Sharps Technology, and Aeries Technology
Via ACCESS Newswire
News headline image
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
New to The Street to Broadcast Saturday, September 27th Featuring NeOnc Pharma $NTHI and Other Innovative Companies
Via ACCESS Newswire
News headline image
NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew” on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
New to The Street to Broadcast Episode 686 Tonight on Bloomberg Television at 6:30 PM EST
Via ACCESS Newswire
News headline image
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
New to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
Via ACCESS Newswire
News headline image
NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire
News headline image
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
From NeOnc Technologies Holdings, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is NeOnc Technologies Holdings, Inc. - Common Stock publicly traded?
Yes, NeOnc Technologies Holdings, Inc. - Common Stock is publicly traded.
What exchange does NeOnc Technologies Holdings, Inc. - Common Stock trade on?
NeOnc Technologies Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for NeOnc Technologies Holdings, Inc. - Common Stock?
The ticker symbol for NeOnc Technologies Holdings, Inc. - Common Stock is NTHI on the Nasdaq Stock Market
What is the current price of NeOnc Technologies Holdings, Inc. - Common Stock?
The current price of NeOnc Technologies Holdings, Inc. - Common Stock is 7.710
When was NeOnc Technologies Holdings, Inc. - Common Stock last traded?
The last trade of NeOnc Technologies Holdings, Inc. - Common Stock was at 12/22/25 04:00 PM ET
What is the market capitalization of NeOnc Technologies Holdings, Inc. - Common Stock?
The market capitalization of NeOnc Technologies Holdings, Inc. - Common Stock is 150.15M
How many shares of NeOnc Technologies Holdings, Inc. - Common Stock are outstanding?
NeOnc Technologies Holdings, Inc. - Common Stock has 150M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.